SCHEMBL6358532

SCHEMBL6358532

CP(=O)(O)CC(CN)c1ccc(F)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABBR2 O75899 5/20 0.53
GABBR1 Q9UBS5 5/20 0.53
LMNA P02545 3/20 0.53
CYP1A2 P05177 2/20 0.53
THRB P10828 2/20 0.53
MAPT P10636 1/20 0.53
PMP22 Q01453 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
GABRR1 P24046 1/20 0.43
AOC3 Q16853 1/20 0.37
CYP2C9 P11712 2/20 0.36
CYP3A4 P08684 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
NFKB1 P19838 1/20 0.36
DRD3 P35462 1/20 0.36
BLM P54132 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1887532 0.83 LMNA (0.76) GABBR2GABBR1LMNACYP1A2THRB
SCHEMBL1881771 0.83 LMNA (0.76) GABBR2GABBR1LMNACYP1A2THRB
SCHEMBL1893272 0.83 LMNA (0.76) GABBR2GABBR1LMNACYP1A2THRB
SCHEMBL9417054 0.76 MEN1 (0.45) GABBR2GABBR1LMNACYP1A2THRB
SCHEMBL11085032 0.75 GABBR2 (0.62) GABBR2GABBR1LMNACYP1A2THRB
SCHEMBL2615283 0.72 GABBR2 (0.55) GABBR2GABBR1AOC3
SCHEMBL5230376 0.72 GABBR2 (0.59) GABBR2GABBR1LMNACYP1A2THRB
SCHEMBL2615282 0.72 GABBR2 (0.55) GABBR2GABBR1AOC3
SCHEMBL21616509 0.72 GABBR2 (0.46) GABBR2GABBR1LMNACYP1A2THRB
SCHEMBL9141278 0.71 GABBR2 (0.40) GABBR2GABBR1LMNACYP1A2THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1372620-A2 METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS Saegis Pharmaceuticals (US) 2004-01-02 EP claimed
US-20020187977-A1 Methods for restoring cognitive function following systemic stress SAEGIS PHARMACEUTICALS, INC. 2002-12-12 US claimed
WO-2002074293-A2 METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS SAEGIS PHARMACEUTICALS INC (US) 2002-09-26 WO claimed
US-20050222093-A1 Methods for restoring cognitive function following systemic stress PEARLMAN RODNEY 2005-10-06 US disclosed
EP-1372620-A2 METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS Saegis Pharmaceuticals (US) 2004-01-02 EP disclosed
US-20020187977-A1 Methods for restoring cognitive function following systemic stress SAEGIS PHARMACEUTICALS, INC. 2002-12-12 US disclosed
WO-2002074293-A2 METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS SAEGIS PHARMACEUTICALS INC (US) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222093-A1 Methods for restoring cognitive function following systemic stress CRH, BDNF, CHAT GABBR2 2093/4885GABBR1 1947/4885LMNA 4098/4885
US-20020187977-A1 Methods for restoring cognitive function following systemic stress CRH, BDNF, CHAT GABBR2 2093/4885GABBR1 1947/4885LMNA 4098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.